Drug intelligence / Profile preview

SBRX19

Development stage: Preclinical
Lead developer: Stramsen Biotech
Administration: Oral

Overview

SBRX19 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of influenza (flu), fever, asthma, and cough. It is part of the company's SBRX series of botanical therapeutics, which are derived from a proprietary database of over 8,000 medicinal plants. The drug is designed to function as both a herbal medicine and a pharmaceutical therapeutic, targeting viral symptoms and respiratory distress. SBRX19 is currently in the early stages of clinical development, with the developer reporting that similar formulations in their pipeline are already in use in certain international markets.

Beyond the preview

Go deeper on SBRX19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX19.

Explore the full profile